Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings or view top-rated stocks.

6 analysts have issued 1-year target prices for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they predict the company's share price to reach $10.71 in the next year. This suggests a possible upside of 42.4% from the stock's current price.
View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts.

Avadel Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, AVDL stock has increased by 5.1% and is now trading at $7.5250.
View the best growth stocks for 2023 here.

Avadel Pharmaceuticals saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 3,340,000 shares, a decrease of 17.5% from the December 31st total of 4,050,000 shares. Based on an average trading volume of 614,300 shares, the short-interest ratio is currently 5.4 days. Currently, 5.9% of the shares of the company are sold short.
View Avadel Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our AVDL earnings forecast.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced its quarterly earnings results on Wednesday, November, 9th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.11.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Edge Wealth Management LLC (0.28%), Kestra Advisory Services LLC (0.03%), Aaron Wealth Advisors LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh.
View institutional ownership trends.

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVDL stock can currently be purchased for approximately $7.53.

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $464.89 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 901-5201, via email at investors@avadel.com, or via fax at 353-1526-1077.